Description

Eterna Peptides presents premium-grade SLU-PP-332 and 5-Amino-1MQ Capsules, an advanced dual-action oral research formulation engineered to study maximum cellular bioenergetics, mitochondrial biogenesis, and metabolic expenditure synergy. Combining two high-purity small molecule compounds—the pioneer Estrogen-Related Receptor (ERR) co-agonist SLU-PP-332 (0.25mg) and the potent Nicotinamide N-methyltransferase (NNMT) inhibitor 5-Amino-1MQ (50mg)—inside a single precisely standardized 50.25mg capsule, this breakthrough matrix serves as an elite investigative tool for tracking fat-burning simulation, skeletal muscle transcription, and obesity resistance kinetics.

### Advanced 50.25mg Dual-Action Metabolic Profile
Each carefully calibrated oral capsule delivers a precise structural distribution of targeted small molecules:
* **5-Amino-1MQ (50mg):** A selective, membrane-permeable small molecule inhibitor of Nicotinamide N-methyltransferase ($NNMT$). By blocking NNMT, it prevents the down-regulation of intracellular Nicotinamide Adenine Dinucleotide ($NAD^+$) cycles, driving active energy expenditure in adipose and skeletal tissues.
* **SLU-PP-332 (0.25mg):** A first-in-class synthetic pan-agonist of Estrogen-Related Receptors ($ERR\alpha$, $ERR\beta$, and $ERR\gamma$). It functions as a powerful exercise mimetic, tricking skeletal muscle tissue into upping its oxidative capacity, mimicking the genomic transcription profiles typically triggered by intensive endurance training.

### Mechanism of Action
The SLU-PP-332 / 5-Amino-1MQ matrix targets complementary metabolic checkpoints to explore advanced fat oxidation and cellular energy production:
* **ERR Activation & Mitochondrial Biogenesis:** SLU-PP-332 upregulates the transcription of estrogen-related receptors, which directly stimulate peroxisome proliferator-activated receptor gamma coactivator 1-alpha ($PGC\text{-}1\alpha$). This master cascade drives structural mitochondrial biogenesis, enhancing the cell’s baseline oxidative capacity and oxygen consumption rate ($OCR$).
* **NNMT Blockade & NAD+ Preservation:** Concurrently, 5-Amino-1MQ selectively blocks NNMT activity, preventing the methylation of nicotinamide. This action spares S-adenosylmethionine ($SAM$) and halts $NAD^+$ depletion cascades, significantly activating SIRT1 longevity signaling and maximizing downstream Adenosine Triphosphate ($ATP$) output.
* **Synergistic Lipid Beta-Oxidation:** Together, the compounds trigger a massive acceleration in lipid oxidation ($ \beta\text{-oxidation} $). SLU-PP-332 increases fatty acid transport genes, while 5-Amino-1MQ forces the cell to look to fat stores for fuel, driving the repartitioning of white adipose tissue into energy-burning matrices.
* **Skeletal Muscle Fiber Shift:** The continuous activation of this small-molecule matrix is monitored for its role in promoting a shift toward highly oxidized, fatigue-resistant slow-twitch (Type I) muscle fibers, studying physical endurance amplification without an actual increase in workload.

### Research Applications
In preclinical and in vitro laboratory models, SLU-PP-332 / 5-Amino-1MQ Capsules are utilized to investigate:
* High-velocity lipid mobilization, white adipose tissue repartitioning, and systemic obesity resistance pathways.
* Exercise mimetic signaling, skeletal muscle oxidative enzyme expression, and fatigue deceleration kinetics.
* Intracellular NAD+ stabilization, sirtuin pathway activation, and mitochondrial chronological longevity models.
* The comparative baseline bioavailability, peak absorption windows, and metabolic rate adaptation of combining NNMT inhibitors with ERR co-agonists.

Our capsules are precision-manufactured under strict laboratory quality control guidelines to ensure an exact 50mg:0.25mg ratio, absolute compound purity, and dependable experimental reproducibility across every research batch.

—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*